
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical Co is positioned for sustained revenue growth, with projected sales increasing to $156 million in 2026, reflecting a 7% year-over-year rise driven by market growth and share gains in the Implantable Collamer lens segment. Key factors supporting this positive outlook include the potential for a faster domestic EVO launch, expanded market share in refractive error correction, and improved margins resulting in stronger earnings per share growth. The company's focus on streamlining operations and enhancing its cost structure further bolsters its ability to capture long-term growth opportunities in the global refractive market.
Bears say
The financial outlook for Staar Surgical Co appears negative due to a series of fundamental challenges impacting revenue growth. The company is facing significant risks, including elevated inventory levels from its new distributor in China, which have led to a notable revenue recognition issue and declining sales forecasts for the upcoming year. Additionally, external pressures such as soft global macroeconomic conditions, patient affordability concerns, and competition from lower-cost alternatives further contribute to a bleak growth trajectory.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares